<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5352">
  <stage>Registered</stage>
  <submitdate>14/01/2016</submitdate>
  <approvaldate>14/01/2016</approvaldate>
  <nctid>NCT02658890</nctid>
  <trial_identification>
    <studytitle>An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread.</studytitle>
    <scientifictitle>A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-004914-79</secondaryid>
    <secondaryid>CA017-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Cancer</healthcondition>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Non-Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986205
Treatment: drugs - Nivolumab
Treatment: drugs - Ipilimumab

Experimental: Combination Therapy (Dose Escalation) - BMS 986205 + Nivolumab specified dose at specified intervals.

Experimental: Combination Therapy (Dose Expansion) - BMS 986205 + Nivolumab specified dose at specified intervals.

Experimental: Combination Therapy 2 (Dose Expansion) - BMS 986205 + both Nivolumab and ipilimumab specified dose at specified intervals


Treatment: drugs: BMS-986205


Treatment: drugs: Nivolumab


Treatment: drugs: Ipilimumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of BMS-986205 as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities. - measured by incidence</outcome>
      <timepoint>100 days after the last dose of study therapy</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety of BMS-986205 plus nivolumab as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities. - measured by incidence</outcome>
      <timepoint>100 days after the last dose of study therapy</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety of BMS-986205 plus both nivolumab and ipilimumab as measured by incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities. - measured by incidence</outcome>
      <timepoint>100 days after the last dose of study therapy</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the best overall response (BOR) - measured by CT scan</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the duration of response (DOR) - measured by CT scan</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by progression-free survival rates (PFSRs) - measured by CT scan</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the best overall response (BOR) - measured by CT scan</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the duration of response (DOR) - measured by CT scan</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by progression-free survival rates (PFSRs) - measured by CT scan</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma concentration (Cmax) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed plasma concentration (Tmax) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough observed plasma concentration at the end of the dosing interval (Ctrough) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Observed plasma concentration at 24 hours (C24) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent terminal phase half-life (T-HALF) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent total body clearance (CLT/F) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent renal clearance (CLR/F) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of distribution of terminal phase (Vz/F) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent volume of distribution at steady state (Vss/F) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Accumulation index (AI) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent urinary recovery (%UR) of BMS-986205 - measured by urine concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent urinary recovery over 24 hours(%UR24) of BMS-986205 - measured by urine concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(0-T)] of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)] of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(INF)] of BMS-986205 - measured by plasma concentration</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-drug antibody (ADA) response to Nivolumab in combination with BMS-986205 - measured by immunoassay and liquid chromatography- mass spectrometry</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-drug antibody (ADA) response to Ipilimumab in combination with BMS-986205 - measured by immunoassay and liquid chromatography- mass spectrometry</outcome>
      <timepoint>Approximately 3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation,
        please visit www.BMSStudyConnect.com

        

          -  During dose escalation, subjects with advanced solid tumors that have progressed
             following at least one standard regimen

          -  During cohort expansion, subjects with advanced cancer that either have received at
             least one prior therapy or are treatment naive, depending on the specified tumor type

          -  Subjects must have measurable disease

          -  Subject must consent to provide previously collected tumor tissue and a tumor biopsy
             during screening.

          -  At least 4 weeks since any previous treatment for cancer

          -  Must be able to swallow pills or capsules

          -  Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active or chronic autoimmune diseases

          -  Uncontrolled or significant cardiovascular disease

          -  History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency
             virus (HIV), or acquired immune deficiency syndrome (AIDS)

          -  Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C
             antibody (except for subjects with hepatocellular carcinoma)

          -  Active central nervous system (CNS) metastases and CNS metastases as the only sites of
             disease

          -  Active infection

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>18/02/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>907</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>28/02/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Darlinghurst</hospital>
    <hospital>Local Institution - North Sydney</hospital>
    <hospital>Local Institution - Westmead</hospital>
    <hospital>Local Institution - Brisbane</hospital>
    <hospital>Local Institution - Clayton</hospital>
    <hospital>Local Institution - Parkville</hospital>
    <hospital>Local Institution - Nedlands</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2146 - North Sydney</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille CEDEX</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex 08</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille Cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 01</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heilbronn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rozzano MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Mazowieckie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine safety and effectiveness of experimental medication
      BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab
      in patients with cancers that are advanced or have spread. Pharmacokinetics and
      pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab
      and Ipilimumab in this patient population will also be assessed.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02658890</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</name>
      <address />
      <phone />
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>